

Beslut vid Fru Berta Kamprads styrelsemöte 23 april 2025

Elsa Arbajian, FBKS 2025-9

Analyses of gene regulation in breast and lung cancer to identify drivers of disease and tumor microenvironment phenotypes
Anslag beviljat 2026-2028

Ylva Bengtsson, FBKS 2025-33

Risk-Reducing Surgeries in Hereditary Breast and Ovarian Cancer: A Swedish National Evaluation of Their Impact on Cancer Incidence, Survival and Title: Risk-Reducing Surgeries in Hereditary Breast and Ovarian Cancer: A Swedish National Evaluation of Their Impact on Cancer Incidence, Survival and Predictors of Decision-Making
Anslag beviljat 2026-2029

Paul Bourguine, FBKS 2025-11

Personalized modeling of CAR-Tc therapy against leukemia using engineered patient mini-bones
Anslag beviljat 2026-2029

Ana Carneiro, FBKS 2025-19

Tumor Infiltrating Lymphocytes in Metastatic Melanoma - an open-label Phase 1b trial
Anslag beviljat 2026-2029

Anna Darabi, FBKS 2025-42

Antisecretory Factor, Chemo-, Radio-, and Immuno-therapy - Investigation of the Combined Treatment Effect in Experimental and Patient-Derived Brain Tumor Models
Anslag beviljat 2026-2029

Tommaso De Marchi, FBKS 2025-16

Proteogenomics investigation of ultrahigh ERBB2Her2 signaling
Anslag beviljat 2026-2027

Sara Ek, FBKS 2025-5

Targeted soluble proteomics, a non-invasive method to optimizing targeted treatment in the relapsed setting - translational studies connected to the Nordic mantle cell lymphoma (MCL) Group VALERIA and PHILEMON clinical trials
Anslag beviljat 2026

Pontus Eriksson, FBKS 2025-24

RNA-sequencing as a modality for implementing treatment prediction in bladder cancer
Anslag beviljat 2026-2028

Anna Gerdtsen, FBKS 2025-17

Investigating STING-directed therapy for ovarian cancer in patient-derived, immune-competent tumor models
Anslag beviljat 2026-2027

Emelie Gezelius, FBKS 2025-4

Improved personalized care of small cell lung cancer

Anslag beviljat 2026-2027

Johan Gustafsson, FBKS 2025-21

Accurate and time-efficient dosimetry in molecular radiotherapy

Anslag beviljat 2026-2027

Valeria Governa, FBKS 2025-30

The unexplored role of the skull bone marrow in brain tumors

Anslag beviljat 2026-2027

Gabriella Honeth, FBKS 2025-32

High-grade serious ovarianpelvic cancer - stem cell patterns, correlations to treatment responses and to additional breast cancer diagnosis

Anslag beviljat 2026-2027

Mats Jerkeman, FBKS 2025-1

Personalized modeling of CAR-Tc therapy against leukemia using engineered patient mini-bones

Anslag beviljat 2026-2029

Helena Jernström, FBKS 2025-36

Delineation of tumor infiltrating lymphocytes in breast cancer risk and prognosis - impact of genetic and lifestyle factors on tumor immune marker levels

Anslag beviljat 2026-2028

Julhash Kazi, FBKS 2025-43

Targeting PLK1-mediated immune evasion in ovarian cancer to enhance immunotherapy

Anslag beviljat 2026-2029

Siker Kimbung, FBKS 2025-34

Unraveling the complex response to preoperative chemotherapy and immunotherapy treatment in early triple-negative breast cancer (TNBC) and molecular characterization of "normal-like" breast cancers

Anslag beviljat 2026-2027

Jenny Klintman, FBKS 2025-29

Integration of Supportive Care into Swedish Cancer Care - A research program to investigate supportive care needs in cancer cohorts as the basis for the development of cost-effective interventions

Anslag beviljat 2026-2027

Fredrik Levander, FBKS 2025-38

Protein biomarker developments for breast cancer patient stratification

Anslag beviljat 2026-2027

Sandra Lindstedt, FBKS 2025-12

Diagnosis in a single breath: A Non-Invasive Approach for Early Diagnosis in Non-Small-Cell Lung Cancer Patients

Anslag beviljat 2026-2029

Niklas Loman, FBKS 2025-37

Nordic Trip a translational randomized phase III study exploring the effect of the addition of Capecitabine to Carboplatin based preoperative chemotherapy in early triple negative breast cancer (TNBC)

Anslag beviljat 2026-2027

Cecilia Magnusson, FBKS 2025-39

Circulating tumor cell precision diagnostics at single cell level

Anslag beviljat 2026-2027

Johan Malm, FBKS 2025-22

Integrating AI and Spatial Proteomics: Unlocking Metastasis Mechanisms for Melanoma Progression Prediction

Anslag beviljat 2026-2029

Malin Malmsjö, FBKS 2025-28

Advancing melanoma diagnostic surgery using non-invasive precision diagnostics

Anslag beviljat 2026-2029

Per Munck af Rosenschöld, FBKS 2025-31

Deep-learning approach to optimized surgery and chemo-radiotherapy of glioblastoma

Anslag beviljat 2026-2029

Martin Nilsson, FBKS 2025-10

Understudied side effects of short course radiotherapy for rectal cancer

Anslag beviljat 2026-2029

Karolin Hansén Nord, FBKS 2025-13

Hur kan stora skador på arvsmassan vara en fördel för cancercellen?

Anslag beviljat 2026-2029

Melinda Rezeli, FBKS 2025-41

Investigating cancer-induced cardiac atrophy: mechanisms, biomarkers, and clinical implications

Anslag beviljat 2026-2029

Mikael Segerlantz, FBKS 2025-3

Early palliative care in advanced gastrointestinal cancer, symptomatic treatment, quality of life for patients and for the next of kin

Anslag beviljat 2026-2029

Gottfrid Sjö Dahl, FBKS 2025-40

Subtype and matrix-dependent interactions modulating platinum sensitivity in urothelial bladder cancer

Anslag beviljat 2026-2028

Martin Sjöström, FBKS 2025-25

Next generation prostate cancer precision medicine

Anslag beviljat 2026-2029

Marie Stenmark Askmalm, FBKS 2025-35

Perception of cancer risk and awareness of healthy lifestyle among individuals with predisposition to hereditary cancer

Anslag beviljat 2026-2029

Joanna Strand, FBKS 2025-26

Systemic targeted radionuclide therapy for prostate cancer

Anslag beviljat 2026-2029

Pia Maly Sundgren, FBKS 2025-20

New advances in CEST and MMI MR imaging for prediction of biomarkers in brain tumor

Anslag beviljat 2026-2027

Vinay Swaminathan, FBKS 2025-15

Development of bench to bedside 3D breast cancer organoid models to investigate tumour-stromal interactions.

Anslag beviljat 2026-2029

Bobby Tingstedt, FBKS 2025-6

EPCP (Enhanced Palliative Care in Pancreatic Cancer)

Anslag beviljat 2026

Jeovanis Gil Valdes, FBKS 2025-18

Precision Diagnostics and Therapeutics Targeting Mitochondrial Vulnerabilities in Melanoma: A Lund-Centric AlphaFold and MAX IV-Guided PROTAC Approach

Anslag beviljat 2026-2029